Publications

Houben GF, Baumert JL, Blom WM, Kruizinga AG, Meima MY, Remington BC, Wheeler MW, Westerhout J, Taylor SL. 2020. Full range of population eliciting dose values for 14 priority allergenic foods and recommendations for use in risk characterization. Food Chem Toxicol 146(Dec)111831; doi: 10.1016/j.fct.2020.111831. PMCID: PMC7864389.

Shoskes A, Migdady I, Rice C, Hassett C, Deshpande A, Price C, et al. 2020. Brain injury is more common in venoarterial extracorporeal membrane oxygenation than venovenous extracorporeal membrane oxygenation: A systematic review and meta-analysis. Crit Care Med 48(12):1799–1808; https://doi.org/10.1097/CCM.0000000000004618.

Neier K, Montrose L, Chen K, Malloy M, Jones T, Svoboda L, et al. 2020. Short- and long-term effects of perinatal phthalate exposures on metabolic pathways in the mouse liver. Environ Epigenet 6(1):dvaa017; doi: 10.1093/eep/dvaa017.

Mallack EJ, Turk BR, Yan H, Price C, Demetres M, Moser AB, et al. 2020. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. J Inherit Metab Dis 44(3):728–739; https://doi.org/10.1002/jimd.12356.

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198; doi: 10.14740/gr1167.

Aerts M, Wheeler MW, Abrahantes JC. 2020. An extended and unified modeling framework for benchmark dose estimation for both continuous and binary data. Environmetrics 31(7):e2630; doi: 10.1002/env.2630. PMCID: PMC9432821.

Bhat VS, Cohen SM, Gordon EB, Wood CE, Cullen JM, Harris MA, Proctor DM, Thompson CM. 2020. An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: A case study with hexavalent chromium, captan, and folpet. Crit Rev Toxicol 50(8)685-706; doi: 10.1080/10408444.2020.1823934.

Parker J, Boles C, Leleck O, Buerger AN, Egnot N, Sunderman A, et al. 2020. Advancing toward normal operations for arenas and stadiums. Toxicol Ind Health 36(9):718–727.

Wikoff D, Lewis JR, Erraguntla N, Franzen A, Foreman J. 2020. Facilitation of risk assessment with evidence-based methods — A framework for use of systematic mapping and systematic reviews in determining hazard, developing toxicity values, and characterizing uncertainty. Regul Toxicol Pharmacol 118:104790; doi: 10.1016/j.yrtph.2020.104790. PMID: 33038430.

Cohen SS, Roger VL, Weston SA, Jiang R, Movva N, Yusuf AA, Chamberlain AM. 2020. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Persp 8(6):e00676; doi: 10.1002/prp2.676.

Guo X, Seo JE, Petibone D, Tryndyak V, Lee UJ, Zhou T, Robison TW, Mei N. 2020. Performance of HepaRG and HepG2 cells in the high-throughput micronucleus assay for in vitro genotoxicity assessment. J Toxicol Environ Health A 83(21-22):702-717; doi: 10.1080/15287394.2020.1822972.

Wheeler MW, Blessinger T, Shao K, Allen BC, Olszyk L, Davis JA, Gift JS. 2020. Quantitative risk assessment: Developing a Bayesian approach to dichotomous dose–response uncertainty. Risk Anal 40(9):1706-22; doi: 10.1111/risa.13537. PMCID: PMC7722241.

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

Eichenbaum G, Yang K, Gebremichael Y, Howell BA, Murray FJ, Jacobson-Kram D, Jaeschke H, Kuffner E, Gelotte CK, Lai JCK, Wikoff D, Atillasoy E. 2020. Application of the DILIsym® Quantitative Systems Toxicology drug-induced liver injury model to evaluate the carcinogenic hazard potential of acetaminophen. Regul Toxicol Pharmacol 118(Dec):104788; doi: 10.1016/j.yrtph.2020.104788.